Hematopoiesis, the production of blood cells, is a dynamic process, the regulation of which under normal conditions must be a tightly controlled process (1-7). Abnormalities in this process no doubt lead to acceleration of malignant and non-malignant disorders. It is over the last 40 yr that these normal and abnormal processes have begun to be unravelled and better defined. This is in large part due to the development of in vitro and in vivo assays that recognize and allow quantitation of different subsets of hematopoietic stem and progenitor cells. Stem cells are defined as cells with multipotential lineage differentiation capacity and the ability to self-renew (make more cells of their own kind). The earliest stem cells would be those with the greatest self-renewal capacity and would include the long-term marrow repopulating cell. Stem cells with less self-renewal and differentiation capacity exist and were originally defined by the in vivo spleen colony forming cell assay in mice. Progenitor cells are considered to have less self-renewal capacity, but the earliest subsets of these can be multipotential.

We now know that hematopoiesis is regulated by an interacting network of cell–cell and cytokine–cell interactions (1-7). Hematopoietic stem and progenitor cells are influenced in their capacity to proliferate, differentiate, and possibly to self-renew, by accessory cell–derived biomolecules, most of which can be classified as cytokines. It is only in the last 15 or so years that our knowledge of cytokines and their actions has blossomed. This is due to the recombinant DNA technology revolution that has allowed the identification, cloning and expression of an increasing number of genes for cytokines and their receptors. We are at a stage where the in vitro actions of cytokines which were first noted in the laboratory are rapidly translated into preclinical and clinical studies to assess the efficacy of these cytokines for potential clinical benefit (8-12). The most obvious of these translational efforts have been with the colony stimulating factors such as erythropoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, and most recently, thrombopoietin.

There are now over 50 bioactive molecules that are known to influence stem or progenitor cell proliferation and differentiation by stimulating, suppressing or enhancing the stimulation or suppression of these cells (1-7, 13). These effects can be direct on the stem or progenitor cells themselves, actions which are most rigorously determined in vitro with an initial culture of a single isolated stem or progenitor cell (14-16), or the effects can be indirectly mediated. This latter effect involves accessory cells which can be induced by a number of stimuli, including cytokines, to produce and release a single, but more likely a group of cytokines (1-7, 17-23) which can then directly act on stem or progenitor cells or have a cascading effect on induction of the production or release of additional cytokines or other biologically active molecules.

Accessory cells can be mature morphologically recognizable blood cells, such as lymphocytes (both T and B cells have been implicated although most is known about T cells), monocytes, macrophages and natural killer cells, or stromal cell elements such as fibroblasts, endothelial cells, epithelial cells, adipocytes and muscle cells (1-7, 17-23). A listing of biologically active molecules with known direct or indirect effects on stem and progenitor cell proliferation and differentiation is shown in Table 1 (1-7, 24-30). This listing is not meant to be all-inclusive as new cytokines are still being discovered. It is in this context that the article by Fossiez et al. (31) in this issue of the Journal of Experimental Medicine, which describes the cloning and action of expressed human IL-17, is of interest. This study follows up on the cloning of murine IL-17 (cytotoxic T-lymphocyte-associated antigen-8, CTLA-8) (32) and complements the recent studies of Yao and colleagues regarding human IL-17 (33) and its novel receptor (34).

Murine IL-17 was identified as part of a search to detect novel molecules involved in functions of the immune system (32). This gene was found as a single copy in cells from mice, rats and humans and was mapped at a single site on mouse chromosome 1A and human chromosome 2q31. Murine IL-17 cDNA contained an opening reading frame that encoded a putative protein of 150 amino acids, which turned out to be 57% homologous to the putative protein encoded by the open reading frame (ORF) 13 gene of a T-lymphotropic virus, herpesvirus Saimiri. This suggested another virus-captured gene with possible functional activity. A number of such virus-captured genes, hypothesized to be important for the residency of viruses in mammalian systems, have been previously reported (reviewed in references 31-34), including that of IL-10, which has 70% homology with an EBV gene, BCRF1 (35). In the paper by
Fossiez et al. (31), the viral counterpart of human IL-17, ORF13, had some activities similar to that of human IL-17, much like BCRF1 and IL-10 that were shown to have some activities in common (35).

Of particular interest is the rather restricted set of cells that produce IL-17 (31-34). This contrasts with the ubiquitous nature of cells expressing the IL-17 receptor gene (34) although whether all cells expressing the IL-17 receptor will respond to IL-17 is not yet known. Moreover, whether the ubiquitous expression of the murine IL-17 receptor gene will also be seen in the human system will need to be evaluated. Of the large number of cell types evaluated for expression of IL-17, it is the T-lymphocytes that appear to be the major source of IL-17 (31, 33); the IL-17 gene under normal conditions needs to be induced for production of IL-17. In particular, it is the activated memory CD4+ T cell subset that has been implicated as an IL-17 producer (31). Whether different stimuli will be able to activate IL-17 production in other cells, and whether IL-17 itself has a role in IL-17 production remains to be determined. A number of cytokines, at first thought to be very restricted in production were later found to be more broadly produced. The exact intracellular molecular mechanisms of IL-17 production have also to be worked out. How much effort is made in this direction may reflect how relevant IL-17 is found to be in the regulation of the immune and hematopoietic systems, and whether or not IL-17 can be used in a clinical sense for treatment of certain disorders.

Upon the discovery of any new biologically active cytokine, high hopes are usually engendered that the cytokine will be of importance to a functional system and that the cytokine, or perhaps a soluble form of the cytokine receptor, may be clinically useful. Whether this turns out to be the case or not will require time and effort. That IL-17 has some interesting characteristics is clear. Human IL-17 and its virus "trapped" counterpart ORF13 have the capacity to induce the production of other cytokines from stromal cell elements, such as fibroblasts, endothelial cells and epithelial cells (31, 33). Thus, it has been determined that IL-17 can induce the release of IL-6, IL-8, G-CSF, and PGE_2, and can also enhance the surface expression of the intracellular adhesion molecule-1 (ICAM-1) (31, 33). Interestingly these induced molecules have different activities. IL-6 has been implicated in a number of activities including growth of hematopoietic stem and progenitor cells and their expansion ex vivo (36-38). IL-8 has been shown to have myelosuppressive activity in vitro and in vivo for stem and immature subsets of myeloid progenitors (7, 26, 39, 40). G-CSF has early and later acting effects on stimulation and acceleration of hematopoiesis, especially of the neutrophil lineage (1-7). Prostaglandin E has demonstrated enhancing activity for erythropoiesis and suppressing activity for lymphopoiesis and myelopoiesis, most specifically for monocytopoiesis (1-7). Thus, through the induction of production of a number of cytokines, a single cytokine can have a broad set of not entirely predictable effects that can be seen as a summation of all events, some of which have the potential of counterbalancing each other.

I can remember a time in the 1970s when scientists considered a molecule to be relevant physiologically only when a very specific function could be demonstrated for that molecule. It was considered that a molecule with many end functions could not be of significance to cell regulation. It is abundantly clear now that all cytokines are relatively pleiotropic in action. So where does this place IL-17 in the overall setting of those cytokines listed in Table 1? Many of those biomolecules listed have, as at least one of their functional capacities, the ability to induce the release of other cytokines from accessory cells, be these stromal or hematopoietic.

| Interleukins (IL)       |                           |
|------------------------|---------------------------|
| IL-1 to IL-17          |                           |
| Colony Stimulating Factors (CSF) |                   |
| Granulocyte (G)-Macrophage (M)-CSF |                |
| G-CSF                  |                           |
| M-CSF                  |                           |
| Eosinophils (Eos)-CSF  | (=IL-5)                   |
| Multi-CSF (=IL-3)      |                           |
| Erythropoietin (Epo)   |                           |
| Thrombopoietin (TPO)   |                           |
| Tumor Necrosis Factor (TNF)-α, -β |             |
| Interferons (IFN)-α, β, γ |                    |
| Transforming Growth Factor (TGF)-β |         |
| Activin                |                           |
| Inhibin                |                           |
| H-Ferritin             |                           |
| Lactoferrin            |                           |
| Prostaglandin (PG)E₁, E₂ |                     |
| Vascular Endothelial Cell Growth Factor (VEGF) | |
| Macrophage Stimulating Protein (MSP) |              |
| Chemokines             |                           |
| Macrophage Inflammatory Protein (MIP)-1α |               |
| MIP-1β                 |                           |
| MIP-2α (=GRO-β)        |                           |
| MIP-2β (=GRO-γ)        |                           |
| GRO-α                  |                           |
| IL-8                   |                           |
| Platelet Factor (PF)-4 |                           |
| γ-Interferon Inducible Protein 10 (IP-10) |             |
| Monocyte Chemotactic Peptide (MCP)-1 (=MCAF) |       |
| MIP-Related Protein (MRP)-1 |                 |
| MRP-2                  |                           |
| ENA-78                 |                           |
| Steel Factor           |                           |
| Flt3-ligand            |                           |

Information on these molecules can be found in references 1-7, 24-30.
Will IL-17 be found to be merely a redundant cytokine floating, after induction of its production, in a “sea” of other redundant cytokines? The full range of cytokine-induction capacities of individual cytokines is not known and perhaps someday some ambitious investigator will have the energy to do a comparative analysis of which cytokines induce the production/release of what cytokines from which cells. Some of this can already be gleaned from the literature, but it would be best for variables to be controlled within a laboratory using the same cytokines and cell preparations. This would give us some insight into the overlapping and non-overlapping inductive capacities of individual cytokines. Redundancy in action itself does not mean the biomolecule is not important. Redundancy is probably the means by which the body protects itself against insults that may disturb the production or action of one or more cytokines or cytokine receptors. Many cytokines can be currently classified in this redundant, but necessary category for “safety fall backs.”

Sometimes, what a cytokine cannot do is as informative to its overall place in an interacting network as to what the cytokine can do. Steel factor (SLF) and Flt3-ligand (L) are both produced by stromal cells (30, 41) and are ligands for tyrosine kinase receptors. SLF and Flt3-L are very potent co-stimulating cytokines for early hematopoietic cells (29, 30). Whether or not SLF and Flt3-L fall into the category of IL-17-inducible proteins would be valuable information. Since cytokines can act synergistically to induce production/release of cytokines (17-20, 31), the effects of multiple cytokines would also have to be taken into consideration. This makes comparative categorizing of the cytokine inductive capacities of different cytokines an even more daunting task. Out of necessity, these studies will have to be done in vitro using highly purified cell populations and their subsets. In the paper by Fossiez et al. (31), TNF-α and IFN-γ were found to have additive effects on the IL-17-induced secretion of IL-6; while neither IL-17 nor TNF-α induced release of GM-CSF, the combination of IL-17 plus TNF-α was effective in this event. Induction of production of cytokines by IL-17, alone and in combination with other cytokines, can be through transcriptional, post-transcriptional or the combination of transcriptional and posttranscriptional effects, and it is highly possible that the mechanisms of cytokine production will not be similar in all cases. The observation by Yao et al. (34) that murine IL-17 stimulates activity of the transcriptional factor NF-κ B, which is known to regulate a number of gene products involved in cell activation and growth control (reviewed in reference 34), offers the possibility that some of the cytokine induction effects of IL-17 may be mediated by a common intracellular event. It has been noted that both glycosylated and non-glycosylated forms of the homodimeric IL-17 molecule are secreted (31, 33). It would be of interest to know if the activities of IL-17 relate to the glycosylated state.

How these in vitro activities relate to the in vivo situation is more difficult to evaluate. One method to evaluate this is to administer IL-17 to mice. Results of such studies could set the stage for clinical evaluation of this molecule. Also, whether a portion of the IL-17 molecule or a small peptide with sequence homology to IL-17 will be shown to have similar activities may be of interest. Peptides that induce the release of cytokines are available (42, 43). A molecule or peptide that induces the release of a number of other cytokines may be of value clinically, as long as the combined effects of the induced molecules don’t cancel each other out (43).

Is the function of IL-17 only to induce the production of other cytokines? Efforts in this area may be clarified through the use of mice in which the genes for IL-17 and/or the IL-17 receptor are “knocked-out.” Whether these “knock-outs” will be embryonic lethal, or result in functional abnormalities could shed light on whether IL-17 is merely another molecule with redundant activities, or if functions of IL-17 not yet recognized are in the offering. The ubiquitous expression of the IL-17 receptor gene (34) suggest the possibility of other functions for IL-17. Moreover, abnormalities could suggest a role for IL-17 in human disease progression.

We thank Linda Cheung and Rebecca Miller for typing the manuscript.

The author is supported by U.S. Public Health Service Grants R01 HL56416, R01 HL54037 and a project in P01 HL53586 from the NHLBI of the National Institutes of Health.

Address correspondence to Hal E. Broxmeyer, Walther Oncology Center, Indiana University School of Medicine, 975 West Walnut St., Indianapolis, IN 46202-5121.

Received for publication 19 April 1996.

References
1. Broxmeyer, H.E., and D.E. Williams. 1988. The production of myeloid blood cells and their regulation during health and disease. CRC Crit. Rev. Oncol./Hematol. 8:173–226.

2. Broxmeyer, H.E. 1990. The interacting effects of cytokines on hematopoietic stem and progenitor cells. In Hematopoietic Growth Factors in Clinical Application. R. Mertelsmann,
and F. Herrmann, editors. Marcel Dekker Inc., New York. 3–24.

3. Broxmeyer, H.E. 1992. Update: Biomolecule-cell interactions and the regulation of myelopoiesis. In Concise Reviews in Clinical and Experimental Hematology. M.J. Murphy, Jr., editor. Alpha Med Press, Dayton, OH. 119–149.

4. Broxmeyer, H.E. 1992. Suppressor cytokines and regulation of myelopoiesis: biology and possible clinical uses. Amer. J. Ped. Hematol. Oncol. 14:22–30.

5. Broxmeyer, H.E. 1993. Role of cytokines in Hematopoiesis. In Clinical Aspects of Cytokines: Role in Pathogenesis, Diagnosis and Therapy. J.J. Oppenheim, J.L. Rossio, and A.J.H. Gearing, editors. Oxford University Press, New York. 201–206.

6. Broxmeyer, H.E. 1995. Role of cytokines in hematopoiesis. In Human Cytokines: Their Role in Disease and Therapy. B.B. Aggarwal, and R.K. Puri, editors. Blackwell Scientific Publications, Inc., Cambridge, MA. 27–36.

7. Broxmeyer, H.E. 1996. Myelosuppressive cytokines and peptides. In Blood Cell Biochemistry. Vol. 7. Hematopoietic Growth Factors. T. Whetton, editor. Plenum, London, UK. In Press.

8. Broxmeyer, H.E., and S. Vadhan-Raj. 1989. Preclinical and clinical studies with the hematopoietic colony stimulating factors and related interleukins. Immunological Res. 8:185–201.

9. Broxmeyer, H.E., and S. Vadhan-Raj. 1991. Clinical utility of hematopoietic growth factors. In Growth Regulation and Carcinogenesis. Vol. II. W.R. Paukovits, editor. CRC University, CRC Press, Inc., Boca Raton, FL. 44–55.

10. Broxmeyer, H.E., L. Lu, S. Vadhan-Raj, and R.-N. Shen. 1992. Hematopoietically active cytokines: Roles for therapy of malignant disease with an emphasis on clinical trials with colony stimulating factors. In Recent Advances in Hematology 6. A.V. Chapter 10. A.V. Hoffbrand, and M.K. Brenner, editors. Churchill Livingstone, London. 195–207.

11. Broxmeyer, H.E. 1995. The cell cycle as therapeutic target. Cancer Invest. 13:617–624.

12. Broxmeyer, H.E., and S. Vadhan-Raj. 1996. Hematopoietic stem and progenitor cell protection. In Manual of GM-CSF. M. Marty, editor. Blackwell Science, Oxford, UK. 197–207.

13. Aronica, S.M., and H.E. Broxmeyer. 1995. Advances in understanding the post-receptor mechanisms of action of GM-CSF, G-CSF and steel factor. Curr. Opin. Hematology. In press.

14. Xiao, M., T. Leemhuis, H.E. Broxmeyer, and L. Lu. 1992. Influence of combinations of cytokines on proliferation of isolated single cell-sorted bone marrow hematopoietic progenitor cells in the absence and presence of serum. Exp. Hematol. 20:276–279.

15. Lu, L., M. Xiao, R.-N. Shen, S. Grigsby, and H.E. Broxmeyer. 1993. Enrichment, characterization and responsiveness of single primitive CD34++ human umbilical cord blood hematopoietic progenitor with high proliferative and replating potential. Blood. 81:41–48.

16. Lu, L., M. Xiao, S. Grigsby, W.X. Wang, B. Wu, R.-N. Shen, and H.E. Broxmeyer. 1993. Comparative effects of suppressive cytokines on isolated single CD34++ stem/progenitor cells from human bone marrow and umbilical cord blood plated with and without serum. Exp. Hematol. 21: 1442–1446.

17. Piacibello, W., L. Lu, M. Wachter, B. Rubin, and H.E. Broxmeyer. 1985. Release of granulocyte-macrophage colony stimulating factors from major histocompatibility complex II-antigen-positive monocytes is enhanced by human gamma interferon. Blood. 66:1343–1351.

18. Piacibello, W., L. Lu, M. Aglietta, B.Y. Rubin, M. Wachter, F. Gavasto, and H.E. Broxmeyer. 1986. Human gamma interferon enhances release of granulocyte-macrophage colony stimulating factors from human T4+ lymphocytes stimulated with phytohemagglutinin. Blood. 68:1339–1347.

19. Lu, L., Walker, D., C.D. Graham, A. Waheed, R.K. Shadduck, P. Ralph, and H.E. Broxmeyer. 1988. Enhancement of release from MHC-class II antigen-positive monocytes of hematopoietic colony stimulating factors by recombinant human tumor necrosis factor-alpha: synergism with recombinant human interferon gamma. Blood. 72:34–41.

20. Lu, L., E.F. Strour, D.J. Warren, D. Walker, C.D. Graham, E.B. Walker, J. Jansen, and H.E. Broxmeyer. 1988. Enhancement of release of granulocyte-colony stimulating factor from sorted subsets of PHA-stimulated human T-lymphocytes by recombinant human tumor necrosis factor-alpha: synergism with recombinant human interferon-gamma. J. Immunol. 141:201–207.

21. Falkenburg, J.H.F., M.A. Harrington, W.K. Walsh, R. Daub, and H.E. Broxmeyer 1990. Gene expression and release of macrophage colony stimulating factor in quiescent and proliferating fibroblasts: effects of serum, fibroblasts growth factors and interleukin-1. J. Immunol. 144:4657–4662.

22. Harrington, M.A., J.H.F. Falkenburg, R. Daub, and H.E. Broxmeyer. 1990. Effect of myogenic and adipogenic differentiation on expression of colony-stimulating factor genes. Mol. Cell. Biol. 10:4948–4952.

23. Falkenburg, J.H.F., M.A. Harrington, W.K. Walsh, R. Daub, J.E. Landegent, R.A. de Paus, and H.E. Broxmeyer. 1991. Differential transcriptional and post-transcriptional regulation of gene expression of the colony-stimulating factors by interleukin-1 and fetal bovine serum in murine fibroblasts. Blood. 78:658–665.

24. Broxmeyer, H.E., B. Sherry, L. Lu, S. Cooper, C. Carow, S.D. Wolpe, and A. Cerami. 1989. Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 in vitro on colony formation by murine and human bone marrow granulocyte-macrophage progenitor cells. J. Exp. Med. 170:1583–1594.

25. Broxmeyer, H.E., B. Sherry, L. Lu, S. Cooper, K.-O. Oh, P. Tekamp- Olson, B.S. Kwon, and A. Cerami. 1990. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vivo by bone marrow myeloid progenitor cells. Blood. 76:1110–1116.

26. Broxmeyer, H.E., B. Sherry, S. Cooper, L. Lu, R. Maze, M.P. Beckmann, A. Cerami, and P. Ralph. 1993. Comparative analysis of the suppressive effects of the human macrophage inflammatory protein family of cytokines (chokemines) on proliferation of human myeloid progenitor cells. J. Immunol. 150:3448–3458.

27. Broxmeyer, H.E., S. Cooper, Z.H. Li, L. Lu, H.-O. Song, B.S. Kwon, R.E. Warren, and D.B. Donner. 1995. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor, a ligand for the tyrosine kinase receptor Flik-1. Int. J. Hematol. 62:203–215.

28. Broxmeyer, H.E., S. Cooper, Z.-H. Li, L. Lu, M.-H. Wang, C. Metz, A. Sarris, S. Lyman, M.-S. Chang, D.B. Donner, and E.J. Leonard. 1996. Macrophage-stimulating protein, a ligand for the RTK tyrosine kinase receptor, suppresses immature myeloid progenitor cell proliferation in vivo, and synergizes in this effect with vascular endothelial cell growth fac-

2414 Commentary
tor and members of the chemokine family. *Annals of Hematol.* In Press.

29. Broxmeyer, H.E., L. Lu, S. Cooper, L. Ruggieri, Z.H. Li, and S.D. Lyman. 1995. Flt-3-ligand stimulates/co-stimulates the growth of myeloid stem/progenitor cells. *Exp. Hematol.* 23:1121–1129.

30. Broxmeyer, H.E., R. Maze, K. Miyazawa, C. Carow, P.C. Hendrie, S. Cooper, G. Hangoc, S. Vadhan-Raj, and L. Lu. 1991. The Kit receptor and its ligand, steel factor, as regulators of hemopoiesis. *Cancer Cells.* 3:480–487.

31. Fossiez, F., O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C. Maat, J.J. Pin, P. Garrone, E. Garcia, S. Sae-land et al. 1996. T-cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. *J. Exp. Med.* 183:2593–2603.

32. Rouvier, E., M.F. Luciani, M.G. Mattei, F. Denizot, and P. Golstein. 1993. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. *J. Immunol.* 150:5445–5456.

33. Yao, Z., S.L. Painter, W.C. Fanslow, D. Ulrich, B.M. Macduff, M.K. Spriggs, and R. Armitage. 1995. Human IL-17: a novel cytokine derived from T cells. *J. Immunol.* 155:5483–5486.

34. Yao, Z., W.C. Fanslow, M.F. Seldin, A.M. Rousseau, S.L. Painter, M.R. Comeau, J.I. Cohen, and M.K. Spriggs. 1995. Herpesvirus Saimiri encodes a new cytokine IL-17, which binds to a novel cytokine receptor. *Immunity.* 3:811–821.

35. Moore, K.W., P. Vieira, D.F. Fiorentino, M.L. Trounstrine, T.A. Khan, and T.R. Mosmann. 1990. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1 [published erratum appears in *Science* Oct. 26, 1990; 250(4980):494] *Science (Wash. DC).* 248:1230–1234.

36. Ikebuchi, K., G.G. Wong, S.C. Clark, J.N. Ihle, Y. Hirai, and M. Ogawa. 1987. Interleukin-6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. *Proc. Natl. Acad. Sci. USA.* 84:9035–9039.

37. Gentile, P., and H.E. Broxmeyer. 1991. Interleukin-6 ablates the accessory cell mediated suppressive effects of lactoferrin on human hematopoietic progenitor cell proliferation *in vitro.* *Ann. N.Y. Acad. Sci.* USA. 628:74–83.

38. Jilka, R.L., G. Hangoc, G. Girasole, G. Passeri, D. Williams, J. Abrams, H.E. Broxmeyer, and S.C. Manolagas. 1992. Increased osteoclast development following estrogen loss: mediation by interleukin-6. *Science (Wash. DC).* 257:88–91.

39. Broxmeyer, H.E., S. Cooper, N. Hague, L. Benninger, A. Sarrìa, K. Cornetta, S. Vadhan-Raj, P. Hendrie, and C. Mantel. 1995. Human chemokines: enhancement of specific activity and effects *in vitro* on normal and leukemic progenitors and a factor dependent cell line and *in vivo* in mice. *Ann. Hematol.* 71:235–246.

40. Daly, T.J., G.J. LaRosa, S. Dolich, T.E. Maione, S. Cooper, and H.E. Broxmeyer. 1995. High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4. *J. Biol. Chem.* 270:23282–23292.

41. Lisovsky, M., S. Braun, Y. Ge, H. Takahira, L. Lu, V.G. Savchenko, S.D. Lyman, and H.E. Broxmeyer. 1996. Flt3-ligand production by human bone marrow stromal cells. *Leukemia.* In Press.

42. Pelus, L.M., A.G. King, H.E. Broxmeyer, P.L. Marsh, S.R. Petteway, and P.K. Bhatnager. 1994. In vivo modulation of hematopoiesis by a novel hematoregulatory peptide. *Exp. Hematol.* 22:239–247.

43. Broxmeyer, H.E. 1992. Combination cytokine therapy or a compound that may indirectly mimic such effects by stimulating production of multiple cytokines? *Exp. Hematol.* 20:149–151.